A New Targeted Therapy Pill Extends Lives of Patients with Metastatic Renal Cell Carcinoma, RCC
Background In the phase III trial, more than 300 patients with metastatic RCC were randomly chosen to receive Fotivda (Tivozanib) or Nexavar (Sorafenib) for a median of 19 months. While…
